Preferences help
enabled [disable] Abstract
Number of results
2015 | 87 | 7 | 340-345
Article title

Assessment Of Plasma B-Catenin Concentration As Biomarker Of Thyroid Cancer*

Title variants
Languages of publication
New diagnostic methods for thyroid diseases are still being searched for. Immunohistochemical diagnosis is expanded by the introduction of new biomarkers including ß-catenin (B-Cat). Associations are indicated between the cellular expression of this biomarker and tumor stage, nodal metastases and the degree of tumor cell differentiation. Reports are scarce regarding the plasma level of this biomarker in malignant neoplastic diseases.The aim of the study was to analyze the plasma B-Cat concentration and the possibility of it use in the diagnostics of patients with nodular goiter and papillary thyroid carcinoma.Material and methods. Plasma B-Cat concentration was determined in 64 patients with goiter and 15 healthy volunteers. The final histopathological examination revealed 41 cases of papillary thyroid carcinoma (PTC) and 13 cases of nodular goiter (NG).Results. A significant increase in B-Cat (p <0.05) in both groups compared to the control group. No differences in the concentrations of biomarker was demonstrated between the PTC and NG groups. After determining the AUC for the tested biomarker, the B-Cat ratio of the area value 0.721 was the strong diagnostic test.Conclusions. Changes in the plasma B-Cat concentration can be the biomarker of thyroid cancer but it cannot be used for the detection of papillary thyroid carcinoma becouse of concomitant tumor-like lesions in the thyroid gland.
Physical description
1 - 7 - 2015
14 - 6 - 2015
7 - 9 - 2015
  • Department of General and Endocrine Surgery, Medical University in ŁódźKierownik: prof. dr hab.
  • 1. Gottardi CJ, Peifer M: Terminal regions of beta-catenin come into view. Structure 2008; 16(3): 336-38.
  • 2. Xing Y, Takemaru K-I, Liu J et al.: Crystal Structure of a Full-Length b-Catenin. Structure 2008; 16 (3): 478-87.
  • 3. Tian X, Liu Z, Niu B, Zhang J et al.: E-cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011; 567305.
  • 4. Forbes SA, Bindal N, Bamford S et al.: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: 945-50.
  • 5. Stopa M, Barczyński M, Konturek A, Nowak W: Ocena częstości przerzutów raka brodawkowatego tarczycy do węzłów. Przegl Lek 2001; 68(12): 1166-69.
  • 6. Gharib H, Papini E, Paschke R et al.: American association of clinical endocrinologists, associazione medici endocrinologi, and european thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules; for the AACE/AME/ETA Task Force on Thyroid Nodules*2010; 16(3): 468-75.
  • 7. Puzianowska-Kuźnicka M, Pietrzak M: Czynniki genetyczne usposabiające do powstania raka brodawkowatego tarczycy. Pol J Endocrinol 2005; 3(56): 339.
  • 8. Kopczyńska E, Kwapisz J, Junik R, Tyrakowski T: Komórkowe markery nowotworowe w raku tarczycy. Pol Merk Lek 2007; 22(130): 295.
  • 9. Prasad M, Pellegata NS, Huang Y et al.: Galectin-3, fibronectin-1, CITED-1, HBME-1 and cytokeratin-19 immunohistochemistry in useful for the 2005; 1(18): 48-57.
  • 10. Bojunga J, Zeuzem S: Molecular detection of thyroid cancer: an update. Clin Endocrinol 2004; 61: 523-30.
  • 11. Rezks S, Brynes RK, Nelson V et al.: Beta-Catenin expression in thyroid follicular lesions: potential role in nuclear changes in papillary carcinoma. Edocr Pathol 2004; 15(4): 329-37.
  • 12. Stanczak A, Stec R, Bodnar L et al.: Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res 2011; 1 (4): 955-63.
  • 13. Pazaitou-Panayiotou K, Mygdakos N, Boglou K et al.: The Immunocytochemistry Is a Valuable Tool in the Diagnosis of Papillary Thyroid Cancer in FNA’s Using Liquid-Based Cytology. J Oncol 2010; 2010: 963926
  • 14. Fujarewicz K, Jarzab M, Eszlinger M et al.: A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection usingsupport vector machines with bootstrapping. Endocr Relat Cancer 2007; 14(3): 809-26.
  • 15. Koziński K, Dobrzyń A: Szlak sygnałowy Wnt i jego rola w regulacji metabolizmu komórki. Postepy Hig Med Dosw 2013; 67: 1098-08.
  • 16. Nowicki A, Sporny S, Duda-Szymańska J: β-catenin as a prognostic factor for prostate cancer (PCa). CE JU 2012; 65(3): 119-23.
  • 17. Elzagheid A, Buhmeida A, Korkeila E et al.: Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol 2008; 14(24): 3866-71.
  • 18. Takayama T, Shiozaki H, Shibamoto S et al.: Beta-catenin expression in human cancers. Am J Pathol 1996; 148(1): 39-46.
  • 19. Nowicki A: Beta-katenina jako czynnik prognostyczny w raku gruczołu krokowego. Przegl Urol 2010; 4(62): 42.
  • 20. Mialhe A, Louis J, Montlevier S et al.: Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis 1997; 17(3): 124-37.
  • 21. Clairotte A, Lascombe I, Fauconnet S: Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 2006; 125(1): 119-26.
  • 22. Lu C, Zhu X, Willingham MC, Cheng SY : Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma. Oncogene 2012; 31(16): 2007-16.
  • 23. Sastre-Perona A, Santisteban P: Wnt-independent role of β-catenin in thyroid cell proliferation and differentiation. Mol Endocrinol 2014; 28(5): 681-95.
  • 24. Dohán O, De la Vieja A, Paroder V et al.: The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003; 24(1): 48-77.
  • 25. Gilbert-Sirieix M, Makoukji J, Kimura S et al.: Wnt/β-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroidcarcinoma cells. PLoS One 2011; 6 (7): 22280.
  • 26. Böhm J, Niskanen L, Kiraly K et al.: Expression and prognostic value of alpha-, beta-, and gamma-catenins indifferentiated thyroid carcinoma. J Clin Endocrinol Metabol 2000; 85(12): 4806-11.
  • 27. Husmark J, Heldin NE, Nilsson M: N-cadherinmediated adhesion and berrant catenin expression in anaplastic thyroid-carcinoma cell lines. Int J Cancer 1999; 83(5): 692-99.
  • 28. Wiseman SM, Masoudi H, Niblock P et al.: Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 2006; 191(5): 581-87.
  • 29. Wu W, Tian Y, Wan H et al.: Expression of β-catenin and E- and N-cadherin in human brainstem gliomas and clinicopathological correlations. Int J Neurosci 2013; 123(5): 318-23.
  • 30. Clevers H: Wnt/β-catenin signaling in development and dise¬ase. Cell 2006; 127: 469-80.
  • 31. Johnson ML, Rajamannan N: Diseases of Wnt signaling. Rev Endocr Metab Disord 2006; 7: 41-49.
  • 32. Polakis P: Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012; 4: a008052.
  • 33. Howard JC, Varallo VM, Ross DC et al.: Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren’s disease cellsare regulated by tension in vitro, BMC Musculoskelet Disord 2003; 16(4): 16.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.